-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cryptococcal meningitis is the most common cause of meningitis in adults in areas of high HIV burden and the second leading cause of HIV-related deaths worldwide, with most deaths occurring in sub-Saharan Africa
We investigated the efficacy of a single high-dose regimen of liposomal amphotericin B in the treatment of HIV cryptococcal meningitis
Non-inferiority endpoint for patient mortality between groups
Between- group patient mortality met non-inferiority endpointCONCLUSIONS: The single-dose liposomal amphotericin B-flucytosine-fluconazole combination regimen is as effective as the current WHO-recommended regimen in the treatment of HIV-associated cryptococcal meningitis, with a lower adverse event rate
The single-dose liposomal amphotericin B-flucytosine-fluconazole combination regimen has the same efficacy in the treatment of HIV-associated cryptococcal meningitis as the current WHO-recommended regimen with a lower adverse event rate
.
The single-dose liposomal amphotericin B-flucytosine-fluconazole combination regimen has the same efficacy in the treatment of HIV-associated cryptococcal meningitis as the current WHO-recommended regimen with a lower adverse event rate
.
Original Source:
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Leave a Comment here